Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Don’t miss cardiovascular risk factors in transgender patients
Key clinical point: Transgender individuals may have elevated cardiovascular risk.
Major finding: The incidence of undiagnosed hypertension and hyperlipidemia was 6.8% and 11.3%, respectively, in transgender individuals who had not yet undergone gender-affirming hormone therapy.
Study details: The data come from a retrospective study of 427 transgender persons seeking gender-affirming hormone therapy.
Disclosures: The study received no outside funding. Lead author Dr. Denby had no financial conflicts to disclose.
Citation:
Denby KJ et al. AHA 2020, Presentation P2274.